Connor, Clark & Lunn Investment Management (CC&L)
BDTX icon

Connor, Clark & Lunn Investment Management (CC&L)’s Black Diamond Therapeutics BDTX Stock Holding History

Connor, Clark & Lunn Investment Management (CC&L)’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Buy
1,092,885
+34,488
+3% +$84.4K ﹤0.01% 1005
2026
Q1 		$2.25M Buy
1,058,397
+403,698
+62% +$960K 0.01% 926
2025
Q4 		$1.59M Buy
654,699
+523,064
+397% +$1.85M ﹤0.01% 993
2025
Q3 		$499K Buy
+131,635
New +$385K ﹤0.01% 1259
2025
Q1 		– Sell
-246,681
Closed -$528K – 1406
2024
Q4 		$528K Sell
246,681
-37,472
-13% -$107K ﹤0.01% 1129
2024
Q3 		$1.24M Sell
284,153
-2,693
-0.9% -$14.7K 0.01% 815
2024
Q2 		$1.34M Sell
286,846
-27,656
-9% -$148K 0.01% 778
2024
Q1 		$1.59M Buy
+314,502
New +$1.27M 0.01% 735
2022
Q4 		– Sell
-82,881
Closed -$140K – 1210
2022
Q3 		$140K Buy
82,881
+70,551
+572% +$218K ﹤0.01% 1025
2022
Q2 		$30K Buy
+12,330
New +$28.7K ﹤0.01% 1015

Other funds holding BDTX

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AIC
AWM Investment Company New York $1.15B AUM 201.65% 1-Year Est. Return

Connor, Clark & Lunn Investment Management (CC&L)'s BDTX Position: Q2 2026 in Review

Connor, Clark & Lunn Investment Management (CC&L) increased its Black Diamond Therapeutics (BDTX) stake by 3.3% in Q2 2026, buying an estimated $84.4K and bringing the position to 1,092,885 shares worth $2.02M. The position accounts for ﹤0.01% of the portfolio, ranked #1005.

Connor, Clark & Lunn Investment Management (CC&L) first reported a position in BDTX in Q2 2022 and has held it in 10 quarters since. The position peaked at $2.25M in Q1 2026. 96 funds tracked by Wall St. Rank hold BDTX as of Q2 2026.

  • Connor, Clark & Lunn Investment Management (CC&L) held 1,092,885 shares of Black Diamond Therapeutics worth $2.02M as of Q2 2026.
  • Connor, Clark & Lunn Investment Management (CC&L) bought 34,488 Black Diamond Therapeutics shares in Q2 2026, an estimated $84.4K.
  • Black Diamond Therapeutics made up ﹤0.01% of Connor, Clark & Lunn Investment Management (CC&L)'s portfolio in Q2 2026, its #1005 holding.
  • Connor, Clark & Lunn Investment Management (CC&L) first reported a position in Black Diamond Therapeutics in Q2 2022 and has held it in 10 quarters since.
  • Connor, Clark & Lunn Investment Management (CC&L)'s Black Diamond Therapeutics position peaked at $2.25M in Q1 2026.
  • 96 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q2 2026.

Based on Connor, Clark & Lunn Investment Management (CC&L)'s 13F filing for Q2 2026, filed 13 Aug 2026.